FDA Approves Subcutaneous Keytruda for Broad Cancer Treatment
TL;DR Summary
The FDA has approved Merck's KEYTRUDA QLEX, a subcutaneous form of pembrolizumab combined with berahyaluronidase alfa, for adults with most solid tumors, offering a faster, more convenient injection option that can be administered in as little as one minute, with comparable efficacy to intravenous pembrolizumab across 38 indications.
Topics:business#cancer-treatment#fda-approval#healthcare#immunotherapy#keytruda-qlex#subcutaneous-injection
- FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) Merck.com
- FDA OKs New Keytruda Shot for Cancer The New York Times
- FDA Approves Subcutaneous Pembrolizumab for Solid Tumors OncLive
- US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda Reuters
- Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug Endpoints News
Reading Insights
Total Reads
0
Unique Readers
32
Time Saved
45 min
vs 46 min read
Condensed
99%
9,053 → 48 words
Want the full story? Read the original article
Read on Merck.com